The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

8307298296888293700f90edfe-fa63-4f46-b794-d091df1f36928b81c621-d7c7-4874-8776-857244600bae5f5c21f3-bf8a-4343-9092-946a33154c32ARGS_News_2015_5_20_General_Releases.pdfARGS_News_2015_5_14_General_Releases.pdfARGS_News_2015_5_13_General_Releases.pdf1798326880183021232015-5-20T8:30:0-4:02015-5-14T16:5:0-4:02015-5-13T17:0:0-4:0914099913314913033General ReleasesGeneral ReleasesGeneral ReleasesPresentations to Highlight Advantages of the Arcelis(R) Technology Platform for Developing and Commercializing Fully Personalized Immunotherapies<p><i>-Interim Data Analyses from the Phase 3 ADAPT Trial At Approximately 25% of Events Expected During ASCO Annual Meeting-</i></p><p><i>- Conference Call and Webcast Today, May 14th, at 4:30 p.m. ET -</i></p>Update to be Presented in Poster Session at American Society of Clinical Oncology Annual Meeting, Positions Trial for Full Enrollment by End of June 2015Argos Therapeutics to Present at the World Stem Cells Regenerative Medicine Congress 2015Argos Therapeutics Reports First Quarter 2015 Financial Results and Operational HighlightsArgos Therapeutics Provides Update on Enrollment Progress for Ongoing Pivotal Phase 3 ADAPT Clinical Trial999999201520152015No Error0

Argos Therapeutics to Present at the World Stem Cells Regenerative Medicine Congress 2015
Read more

Argos Therapeutics Reports First Quarter 2015 Financial Results and Operational Highlights
Read more

Argos Therapeutics Provides Update on Enrollment Progress for Ongoing Pivotal Phase 3 ADAPT Clinical Trial
Read more

> More News & Events >>>

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC